Requip XL;治療藥物分析及市場預測 是由出版商GlobalData在2011年07月所出版的。
這份英文市場調查報告書包含Pages: 35 價格從美金2000起跳。
本報告提供帕金森氏症治療藥物的 Requip XL 平台分析及市場預測，以市場特徵為首，評估分析競爭，開發平台等，加上未來市場競爭，企業簡介等資料，為您概述為以下內容。
1 目錄 1 目錄 2 簡介
- 2.1 帕金森氏症
- 2.2 症狀; 帕金森氏症
- 2.3 診斷; 帕金森氏症
- 2.4 帕金森氏症 治療策略
- 2.5 帕金森氏症 市場
- 2.6 免疫學
- 2.7 帕金森氏症, 年齡及性別
- 2.8 病因論
- 2.9 GlobalData 報告指南
3 帕金森氏症: 市場特性
- 3.1 帕金森氏症 市場
- 3.2 帕金森氏症 市場 預測及年複合成長率
- 3.3 影響因素; 帕金森氏症 市場
- 3.3.1 高患病率: 帕金森氏症是第二大常見的神經退化性疾病
- 3.3.2 老年人口的增加
- 3.3.3 專利期間的結束; 潛力治療藥物
4 分期; 帕金森氏症及治療方法比較
- 4.1 Hoehn-Yahr 分期法
- 4.2 修正 Hoehn-Yahr 分期法
- 4.3 UPDRS;帕金森氏症統一分期法
5 分期分類; 帕金森氏症
- 5.1 分佈; 帕金森氏症 患者, 各年齡層
- 5.2 各階段患者分佈
6 Requip XL
- 6.1 簡介
- 6.2 作用機制
- 6.3 臨床研究
- 6.3.1 調查研究 - 初期的帕金森氏症患者
- 6.3.2 調查研究 - 進行的帕金森氏症患者
- 6.4 認證經歷; Requip XL
- 6.5 銷售額的影響因素; Requip XL
- 6.5.1 多劑處方的使用
- 6.5.2 首發者利益
- 6.5.3 有效性簡介
- 6.5.4 服用的便利性
- 6.5.5 短的產品生命週期
- 6.5.6 Requip IR 的學名藥品的競爭
- 6.5.7 認證 - 日本
- 6.6 醫藥品評估
- 6.6.1 藥物的風險·好處評估
- 6.6.2 競爭激烈度
- 6.7 銷售額預期
- 6.7.1 目標患者群; 帕金森氏症
- 6.7.2 投藥
- 6.7.3 市場滲透率
- 6.7.4 治療的年度成本;
- 6.7.5 銷售額預期; Requip XL
7 帕金森氏症 市場: 附錄
- 7.1 市場定義
- 7.2 簡稱一覽
- 7.3 調查方法
- 7.3.1 調查範圍
- 7.3.2 二級研究
- 7.3.3 預測
- 7.3.4 可服用藥物的患者數
- 7.3.5 治療藥物的純市場滲透率
- 7.3.6 年度淨投藥數量
- 7.3.7 治療的年度成本;
- 7.3.8 主要研究
- 7.3.9 專家委員會
- 7.4 治療藥物的銷售額預期模式
- 7.5 諮詢方式
- 7.6 免責聲明
- 7.7 資訊來源
1.1 表格一覽
- 表格 1: 臨床運動及非運動症狀; 帕金森氏症
- 表格 2: 帕金森氏症的 Hoehn - Yahr 重症期
- 表格 3: 帕金森氏症的 Hoehn - Yahr 重症期
- 表格 4: UPDRS 之1，第4項
- 表格 5: 帕金森氏症 之2，第13項
- 表格 6: UPDRS 之3，第14項
- 表格 7: UPDRS 之3，第14項
- 表格 8: 分佈; 依Hoehn and yahr分期法分期的帕金森氏症患者
- 表格 9: 有效性的主要評估結果; Requip XL - 進行的帕金森氏症
- 表格 10: 認證經歷; Requip XL
- 表格 11: 藥物的風險·好處評估; Requip XL
- 表格 12: 有效性比較; Requip XL 及其他多巴胺作用藥
- 表格 13: 有效性比較; Requip XL 及其他競爭產品
- 表格 14: 年度成本; Requip XL
- 表格 15: Requip XL, 帕金森氏症, 全球市場, 銷售額預期 ($m)
- 表格 16: Requip XL, 帕金森氏症, 美國, 銷售額預期 ($m)
- 表格 17: Requip XL, 帕金森氏症, 英國, 銷售額預期 ($m)
- 表格 18: Requip XL, 帕金森氏症, 法國, 銷售額預期 ($m)
- 表格 19: Requip XL, 帕金森氏症, 德國, 銷售額預期 ($m)
- 表格 20: Requip XL, 帕金森氏症, 義大利, 銷售額預期 ($m)
- 表格 21: Requip XL, 帕金森氏症, 西班牙, 銷售額預期 ($m)
1.2 圖表一覽
- 圖 1: 最新的藥物療法; 帕金森氏症及潛在的作用部位 - CNS(中樞神經系統)
- 圖 2: 各年齡患病率; 帕金森氏症 - EU5個國家的老年人
- 圖 3: 帕金森氏症, 全球市場, 市場規模預測 ($bn)
- 圖 4: 60歲以上人口的比例, 全球, 1950-2050
- 圖 5: UPDRS的分數分佈
- 圖 6: 分佈; 依Hoehn and yahr分期法分期的帕金森氏症患者
- 圖 7: Drug model diagram; Requip XL - 美國及EU
- 圖 8: Requip XL, 帕金森氏症, 全球市場, 銷售額預期 ($m)
- 圖 9: Requip XL, 帕金森氏症, 美國, 銷售額預期 ($m)
- 圖 10: Requip XL, 帕金森氏症, 英國, 銷售額預期 ($m)
- 圖 11: Requip XL, 帕金森氏症, 法國, 銷售額預期 ($m)
- 圖 12: Requip XL, 帕金森氏症, 德國, 銷售額預期 ($m)
- 圖 13: Requip XL, 帕金森氏症, 義大利, 銷售額預期 ($m)
- 圖 14: Requip XL, 帕金森氏症, 西班牙, 銷售額預期 ($m)
- 圖 15: Requip XL, 帕金森氏症, 全球市場, 各國銷售額分佈 (%)
- 圖 16: Drug model diagram
- 圖 17: 可服用藥物的患者數
Abstract
Summary
GlobalData's pharmaceuticals report, "Requip XL - Analysis and Estimates from 2007 to 2020" provides Requip XL sales estimates for US and EU5 . In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes information on Parkinson's Disease market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Scope
- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Requip XL including historical sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Requip XL including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2007-2020 for Requip XL in the US & EU5
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of contents
1. Table of contents
- 1.1 List of Tables
- 1.2 List of Figures
2. Introduction
- 2.1 Parkinson's Disease
- 2.2 Symptoms of Parkinson's Disease
- 2.3 Diagnosis of Parkinson's disease
- 2.4 Parkinson's Disease Treatment Strategies
- 2.5 Parkinson's Disease Market
- 2.6 Epidemiology
- 2.7 Parkinson's Disease by Age and Gender
- 2.8 Etiology
- 2.9 GlobalData Report Guidance
3. Parkinson's Disease: Market Characterization
- 3.1 Parkinson's Disease Market
- 3.2 Parkinson's Disease Market Forecasts and CAGR
- 3.3 Factors Affecting Parkinson's Disease Market
- 3.3.1 High Prevalence: PD is the Second Most Frequent Neurodegenerative Disorder
- 3.3.2 Increase in Old Age Population
- 3.3.3 Patent Expiry of Prominent Drugs
4. Stages of Parkinson's Disease and Comparison of Treatments
- 4.1 The Hoehn and Yahr Scale
- 4.2 Modified Hoehn and Yahr Scale
- 4.3 The UPDRS
5. Staging of Parkinson's Disease
- 5.1 Distribution of Parkinson's disease Patients by Age Groups
- 5.2 Distribution of Patients by Stages
6. Requip XL
- 6.1 Introduction
- 6.2 Mechanism of Action
- 6.3 Clinical Studies
- 6.3.1 Study in Patients with Early Parkinson's Disease
- 6.3.2 Study in Patients with Advanced Parkinson's Disease
- 6.4 Approval History of Requip XL
- 6.5 Factors Affecting Sales of Requip XL
- 6.5.1 Used in Multiple Regimens
- 6.5.2 First Mover Advantage
- 6.5.3 Efficacy Profile
- 6.5.4 Dosing Convenience
- 6.5.5 Short Product Life Cycle
- 6.5.6 Generic Competition from Requip IR
- 6.5.7 Approval in Japan
- 6.6 Drug Evaluation
- 6.6.1 Drug Risk Benefit Score
- 6.6.2 Intensity of Competition
- 6.7 Sales Estimates
- 6.7.1 Target Patient Pool for Parkinson's Disease
- 6.7.2 Dosing
- 6.7.3 Market Penetration
- 6.7.4 Annual Cost of Therapy
- 6.7.5 Sales Estimates of Requip XL
7. Parkinson Disease Market: Appendix
- 7.1 Market Definitions
- 7.2 List of Abberiviations
- 7.3 Research Methodology
- 7.3.1 Coverage
- 7.3.2 Secondary Research
- 7.3.3 Forecasting
- 7.3.4 Number of Patients Approved to take the Drug
- 7.3.5 Net Penetration of Drug
- 7.3.6 Net Annual Dosing
- 7.3.7 Annual Cost of Therapy
- 7.3.8 Primary Research
- 7.3.9 Expert Panels
- 7.4 Drug Sales Estimates Model
- 7.5 Contact Us
- 7.6 Disclaimer
- 7.7 Sources
List of Tables
- Table 1: Clinical Motor and Nonmotor Features of Parkinson's Disease
- Table 2: Hoehn and Yahr Stages of Parkinson's Disease
- Table 3: Hoehn and Yahr Stages of Parkinson's Disease
- Table 4: Four Items, Part 1 of UPDRS
- Table 5: Thirteen Items, Part 2 of Parkinson's disease
- Table 6: Fourteen Items, Part 3 of UPDRS
- Table 7: Fourteen Items, Part 3 of UPDRS
- Table 8: Distribution of Parkinson's patients according to Hoehn and Yahr Classification
- Table 9: Primary Efficacy Endpoint Results for Requip XL in Advanced Parkinson's Disease
- Table 10: Approval History of Requip XL
- Table 11: Drug Risk Benefit Score of Requip XL
- Table 12: Efficacy Comparison of Requip XL with other Dopamine Agonists
- Table 13: Efficacy Comparison of Requip XL with other Competitors
- Table 14: Annual Cost of Requip XL for Parkinson's Disease, 2011
- Table 15: Requip XL, Parkinson's Disease, Global, Sales Estimates ($m), 2007-2020
- Table 16: Requip XL, Parkinson's Disease, The US, Sales Estimates ($m), 2008-2020
- Table 17: Requip XL, Parkinson's Disease, The UK, Sales Estimates ($m), 2007-2020
- Table 18: Requip XL, Parkinson's Disease, France, Sales Estimates ($m), 2007-2020
- Table 19: Requip XL, Parkinson's Disease, Germany, Sales Estimates ($m), 2007-2020
- Table 20: Requip XL, Parkinson's Disease, Italy, Sales Estimates ($m), 2007-2020
- Table 21: Requip XL, Parkinson's Disease, Spain, Sales Estimates ($m), 2007-2020
List of Figures
- Figure 1: Current Pharmacologic Therapies for Parkinson's disease and Their Potential Sites of Action in the CNS
- Figure 2: The Age-Specific Prevalence Rates of Parkinson's Disease in the Elderly Among Five European Countries, 2003
- Figure 3: Parkinson's Disease, Global, Market Size Estimates ($bn), 2010-2020
- Figure 4: Proportion of Population 60 Years or Older, World, 1950-2050
- Figure 5: Points Distribution of UPDRS
- Figure 6: Distribution of Parkinson's patients by Hoehn & Yahr Classification
- Figure 7: Drug Model Diagram of Requip XL in the US and EU
- Figure 8: Requip XL, Parkinson's Disease, Global, Sales Estimates ($m), 2007-2020
- Figure 9: Requip XL, Parkinson's Disease, The US, Sales Estimates ($m), 2008-2020
- Figure 10: Requip XL, Parkinson's Disease, The UK, Sales Estimates ($m), 2007-2020
- Figure 11: Requip XL, Parkinson's Disease, France, Sales Estimates ($m), 2007-2020
- Figure 12: Requip XL, Parkinson's Disease, Germany, Sales Estimates ($m), 2007-2020
- Figure 13: Requip XL, Parkinson's Disease, Italy, Sales Estimates ($m), 2007-2020
- Figure 14: Requip XL, Parkinson's Disease, Spain, Sales Estimates ($m), 2007-2020
- Figure 15: Requip XL, Parkinson's Disease, Global, Sales Distribution by Country (%), 2010
- Figure 16: Drug Model Diagram
- Figure 17: Patients Approved for the Drug
|
